scholarly journals P13: THE EFFECT OF PEGFILGRASTIM ON COMPLETE BLOOD COUNT IN COLORECTAL CANCER PATIENTS TREATED WITH FOLFOX OR FOLFIRI CHEMOTHERAPY

2016 ◽  
Vol 64 (3) ◽  
pp. 822.2-822
Author(s):  
V Kremer ◽  
I Shapira ◽  
A Leaf
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Blood Count ◽  
Complete Blood Count ◽  
Phase Iii ◽  
Hematopoietic Stem ◽  
Platelet Counts ◽  
Leukocyte Counts ◽  
The Mean ◽  
Colorectal Cancer Patients

Purpose of StudyIn both FOLFOX and FOLFIRI regimens used for colorectal cancer, the 5-FU is infused over 46 hours every 14 days. Given the 10–20% risk of neutropenic fever, these regimens may be given with pegfilgrastim support. There is evidence to support its use for 21 day cycles, but no phase III trials demonstrating its efficacy and safety for regimens given every 14 days, a potential concern, given the hypothesis that the hematopoietic stem cells mobilized by pegfilgrastim into the peripheral blood may undergo cell cycle arrest, apoptosis and death while under effect of chemotherapy. Pegfilgrastim regulates the proliferation, differentiation, and survival of the myeloid lineage. It mobilizes hematopoietic progenitor cells in the peripheral circulation, has a long half-life, and is given on day 4 of 14-day infusional 5-FU based regimens. Given the fact that cytotoxic chemotherapy is administered on day 11 after pegfilgrastim, we performed a retrospective study evaluating the correlation between decrease in complete blood count and chemotherapy administered at 11 day intervals after pegfilgrastim.Methods UsedThe medical records of colorectal cancer patients were reviewed from 2003–2013. Data collected included age, stage, ethnicity, complete blood count, chemotherapy, and use of pegfilgrastim.Summary of ResultsData from 50 eligible charts was collected. Twenty one patients were treated with chemotherapy and pegfilgrastim, 29 patients had chemotherapy alone. Prior to chemotherapy, both groups had a mean leukocyte count of 6.6×109/L and 6.8×109/L and a mean platelet count of 313,000/mm3 and 255,000/mm3 respectively. At 9 months mean leukocyte counts were 6.3×109/L and 5.4×109/L and the mean platelet counts were 186,000/mm3 and 170,000/mm3 respectively. At 24 months, the mean leukocyte counts were 6.7×109/L and 5.7×109/L and the mean platelet counts were 220,000/mm3 and 196,000 mm3 respectively.ConclusionsWhen given on day 4 of a 14 day cycle, there was no effect of pegfilgrastim on complete blood counts in this small retrospective cohort study; finding a more subtle effect would require a larger sample size.

VICTOR: A phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4038-4038 ◽  
Author(s):  
D. J. Kerr ◽  
J. A. Dunn ◽  
M. J. Langman ◽  
J. L. Smith ◽  
R. S. Midgley ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Controlled Trial ◽  
Phase Iii ◽  
Colorectal Cancer Patients

Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10056-10056
Author(s):  
Afsaneh Barzi ◽  
Dawn L. Hershman ◽  
Cathee Till ◽  
Heinz-Josef Lenz ◽  
Howard S. Hochster ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Fracture Risk ◽  
Cancer Patients ◽  
Phase Iii ◽  
P Value ◽  
National Hospital Discharge Survey ◽  
Prostate Cancer Prevention ◽  
The Difference ◽  
Using Data ◽  
Colorectal Cancer Patients

10056 Background: There are currently 1.5 million CRC survivors in US and this number will continue to rise with advancements in treatment. The risk of OP in CRC survivors has not been well described. Methods: We used data from 3 SWOG CRC treatment trials, all of which were phase III and had long term follow-up. Enrollees were linked to Medicare claim files for identification of OP and fractures using HCPCS and ICD9 codes. First, we compared patterns of osteoperosis and fracture risk by sex in colorectal cancer patients. To assess whether patterns of fracture risk by sex differed between patients with vs. without colorectal cancer, we compared the difference in fracture risk by sex in colorectal cancer patients to the difference in fracture risk by sex in the general U.S. population, using data from the National Health Interview Survey (NHIS) and the National Hospital Discharge Survey (NHDS). Finally, we assessed whether absolute estimates of osteoperosis and fracture risk differed between men with colorectal cancer and men without colorectal cancer. Comparison data for men without colorectal cancer were obtained from the placebo arm of the Prostate Cancer Prevention trial (PCPT). Results: We linked 1233 CRC cases with Medicare claims. The median age at CRC diagnosis was marginally higher for women (65 vs 64 ys, p = 0.03). 47% of females, 15% of men with CRC, and 19% of men without CRC had a OP diagnosis. The female to male ratio of osteoporotic fracture in general U.S. population was 1.67, while the same ratio in CRC survivors was 2.84, an increase of 70% (p-value < 0.001). Conclusions: Our study indicates that the risk disparity for OP fracture for females is much greater in CRC survivors than in the general U.S. population. This may be due to more OP diagnoses for female CRC survivors, but not for male CRC survivors.

The prognostic impact of KRAS mutation in colorectal cancer patients: A meta-analysis of phase III clinical trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14515-e14515 ◽  
Author(s):  
Clarinda Wei Ling Chua ◽  
Dawn QQ Chong ◽  
Ravindran Kanesvaran ◽  
Wai Meng David Tai ◽  
Chee Kian Tham ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Kras Mutation ◽  
Meta Analysis ◽  
Phase Iii ◽  
Prognostic Impact ◽  
Phase Iii Clinical Trials ◽  
Colorectal Cancer Patients

Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15130-e15130
Author(s):  
Jihene Braham Ayari ◽  
Rania Guesmi ◽  
Mehdi Balti ◽  
Mouna Ben Azaiz ◽  
Aref Zribi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Solid Phase ◽  
Young Patients ◽  
Serum Samples ◽  
Metastatic Setting ◽  
The Mean ◽  
High Level ◽  
Colorectal Cancer Patients ◽  
Circulating Cytokines

e15130 Background: Colorectal cancer is the third most common malignancy and fourth most common cause of cancer mortality worldwide. It is responsible for more than 600,000 deaths annually, and incidence rates are increasing in most of the developing countries. Pathophysiology implicates pro-inflammatory conditions that promote the tumor malignant progression, invasion, and metastasis. The aim of this study is to measure the level of circulating cytokines (IL1b, IL6, IL8, IL10, IL22, IL23 and TNFα) in sixty colorectal cancer patients in Tunisia and to evaluate their implication as prognostic factors. Methods: Serum samples were collected prospectively from a cohort of sixty colorectal cancer patients in Tunisia. Levels of circulating inflammatory cytokines, TNF-α, IL1b, IL6 and IL8 were measured using the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, Simens, USA). Serum levels of IL10 were measured by enzyme-linked immunosorbent assays (ELISA) sandwich method. Results: The mean age of patients is 58 years (24–82 years), Thirty-sex among them were m and 24 women with sex ratio of 1.5. Twenty-five patients were at metastatic setting, and hepatic metastasis was found in 25% of cases. The mean level of cytokines Il6, IL10, TNFα, IL8 and IL1b were respectively 12.26 +/- 18.7 pg/ ml (min 2, max 117pg/ ml), 0.93 +/- 5.23 pg/ ml (min 0, max 39.35 pg/ml), 8.31 +/- 4.99 pg/ ml (min 4, max 27.20 pg/ ml), 61.9 +/- 159.71 pg/ml (min 5, max 1173 pg/ ml) and 1.13 +/- 3.34 pg/ ml (min 5, max 15.7pg/ml. We found a significant correlation between a high level of IL8 and metastatic disease (p=0.001), especially in mutant RAS cases (p=0.001). We found also a significant correlation between high level of IL1b and lymphovascular invasion (p=0.013) and young patients (p=0.01). On the other hand, there was significant correlation between IL8 and IL6 (r = 0.560, p = 0.00001); IL8 and TNFα (r = 0.404, p = 0.001); and IL10 with IL1b (r = 0.297, p = 0.021). Conclusions: Our results highlight the role of circulating IL8, TNFα, IL1b and IL10 as potential prognostic biomarkers in colorectal cancer patients. These cytokines could contribute to tumor growth and progression, namely for IL-8 level that was significantly correlated with poor prognosis and advanced stages. This correlation needs to be evaluated in large prospective trials and suggests a rational for the development and use of cytokine blockade in treatment of colorectal cancer patients.

Sign in / Sign up

Export Citation Format

Share Document